Patents by Inventor Janet Douglas

Janet Douglas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220288195
    Abstract: The present disclosure relates to isolated polynucleotides and polypeptides, and related hepatitis B virus (HBV)vaccines. The present disclosure also relates to viral vectors for expressing such polypeptides, and which may be used in HBV vaccines, as well as methods of protecting a subject from HBV infection and methods of treating HBV in a subject comprising administering the polypeptides, vectors, or vaccines described herein. Methods of designing and producing an HBV vaccine comprising designing vaccine antigens to cover the diversity within a geographic area using an antigen amino acid sequence that efficiently covers the epitopes in the HBV genotypes present in the geographic area are also provided herein.
    Type: Application
    Filed: August 28, 2020
    Publication date: September 15, 2022
    Inventors: Eric BRUENING, Janet DOUGLAS, Emily MARSHALL, Karina YUSIM, Bette KORBER, James THEILER
  • Publication number: 20080021207
    Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.
    Type: Application
    Filed: February 5, 2007
    Publication date: January 24, 2008
    Applicant: Novartis AG
    Inventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Douglas
  • Publication number: 20070281911
    Abstract: The active metabolites of adefovir and tenofovir (PMEApp and PMPApp) are active against the MMTV RT. They are 25-fold more potent than 3TCppp, suggesting that tenofovir and adefovir may be effective at inhibiting the MMTV-like retroviruses, which may be the etiological agents involved in PBC and breast cancer.
    Type: Application
    Filed: January 21, 2005
    Publication date: December 6, 2007
    Applicant: GILEAD SCIENCES INC.
    Inventors: Tomas Cihlar, Janet Douglas, Craig Gibbs
  • Publication number: 20070010017
    Abstract: The present invention provides novel lentiviral packaging constructs that are useful for the establishment of stable packaging cell lines and producer cell lines. In particular, the present invention provides novel packaging cell lines that are capable of constitutively expressing high levels of lentiviral proteins.
    Type: Application
    Filed: June 30, 2006
    Publication date: January 11, 2007
    Applicant: Novartis AG
    Inventors: Michael Kaleko, Tianci Luo, Ivan Plavec, Janet Douglas
  • Publication number: 20050239753
    Abstract: The active metabolites of adefovir and tenofovir (PMEApp and PMPApp) are active against the MMTV RT. They are 25-fold more potent than 3TCppp, suggesting that tenofovir and adefovir may be effective at inhibiting the MMTV-like retroviruses, which may be the etiological agents involved in PBC and breast cancer.
    Type: Application
    Filed: January 21, 2005
    Publication date: October 27, 2005
    Inventors: Tomas Cihlar, Janet Douglas, Craig Gibbs